Compare FSI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | ACRV |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 74.0M |
| IPO Year | 2000 | 2022 |
| Metric | FSI | ACRV |
|---|---|---|
| Price | $6.18 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 10.4K | ★ 326.7K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $24.09 | N/A |
| Revenue Next Year | $60.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.85 | $1.27 |
| 52 Week High | $9.89 | $3.56 |
| Indicator | FSI | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 61.48 | 46.59 |
| Support Level | $5.95 | $1.61 |
| Resistance Level | $6.67 | $2.21 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 53.75 | 30.43 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.